Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chung

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Pharmaceutics|May 28, 2022
3,6'- and 1,6'-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt InflammationYan-Rou Tsai, Dong Seok Kim, Shih-Chang Hsueh, et al.
Lancet (London, England)|November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancerAndrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Nathalie Gaspar, Katherine Janeway, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Pharmaceutics|May 28, 2022
3,6'- and 1,6'-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt InflammationYan-Rou Tsai, Dong Seok Kim, Shih-Chang Hsueh, et al.
Lancet (London, England)|November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancerAndrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Nathalie Gaspar, Katherine Janeway, et al.
Pageof 7